RBC Capital on Ultragenyx Pharma (RARE): 'We Believe RARE Has A Drug For Osteogenesis Imperfecta'
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $77.00 price target on Ultragenyx Pharma (NASDAQ: RARE).The analyst said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
